International Stem Cell Corporation (ISCO)

Market Cap	640.35K
Revenue (ttm)	8.32M
Net Income (ttm)	-467.00K
Shares Out	8.00M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,980
Open	0.0600
Previous Close	0.0600
Day's Range	0.0600 - 0.0700
52-Week Range	0.0500 - 0.1500
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About International Stem Cell

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson’s disease, as well as for treating stroke, traumatic brain injury, and Alzheimer’s disease. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Comple...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 29
• Stock Exchange: OTCMKTS
• Ticker Symbol: ISCO

Financial Performance

In 2023, International Stem Cell's revenue was $7.79 million, a decrease of -4.78% compared to the previous year's $8.18 million. Losses were -$131,000, -60.42% less than in 2022.